Stable Dividend Growth with AVY in the Bioarma Space

21 days ago

Chris Marotch

"I obviously didn't understand the assignment because I went in a completely different direction than they did. If I was actually going for that trade, I might be looking at some of the uranium miners, but that could take this conversation in a totally different direction that we don't want it to go. I went for a tried-and-true stock. It's one that I've loved for many years. It's Avy and it's in the bioarma space. The stock's done very well this year. Actually, pretty surprising in a beaten down industry. The pharmaceutical industry in general has not had a good year, but AVY's been a shining star in that sector and it's projected to continue to do so in 2026."

Chris presents AVY as a reliable, long-term bioarma play with solid dividend growth. Despite a challenging sector, AVY's resilient performance and robust pipeline position it as a must-own for dividend-focused investors.

Related Stocks